Altimmune, Inc.

Listed Company

ALTCIK 0001326190NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$41.0K

Net Income

$-88.09M

Total Assets

$279.93M

Equity

$224.89M

Shares Out

194.47M

Op. Cash Flow

$-67.53M

ALT$2.87−29.31% · past yearDBEQ Basic

Daily closing prices

Business

Altimmune, Inc. is a late-stage biopharmaceutical company developing pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist peptide therapeutic, for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company is advancing pemvidutide through Phase 2b and Phase 2 clinical trials. Altimmune protects pemvidutide through a robust patent portfolio extending into the 2040s and operates primarily in the United States regulatory environment under FDA oversight.

Summary from 10-K filed 2026-03-06

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	41,000	20,000	426,000	−68,000	4
Research and development	66	82	66	71	75
General and administrative	28	21	18	17	15
Total operating expenses	95	103	96	88	101
Loss from operations	−94	−103	−96	−88	−97
Interest expense	−2	−9,000	−35,000	—	—
Interest income	8	8	7	3	203,000
Other income (expense), net	−190,000	48,000	166,000	−32,000	−374,000
Total other income (expense), net	6	8	7	3	−176,000
Net loss before income taxes	−89	−95	−88	−85	−97
Income tax expense (benefit)	−681,000	—	—	−200,000	—
Net loss	−88	−95	−88	−85	−97
Other comprehensive income - unrealized gain on short-term investments	45,000	31,000	223,000	−187,000	4,000
Comprehensive loss	−88	−95	−88	−85	−97
Net loss per share, basic	−1	−1.34	−1.66	−1.81	−2.35
Net loss per share, diluted	−1	−1.34	−1.66	−1.81	−2.35
Weighted-average common shares outstanding, basic	88	71	53	47	41
Weighted-average common shares outstanding, diluted	88	71	53	47	41

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	44	37	135	111	190
Restricted cash	42,000	42,000	41,000	34,000	34,000
Total cash, cash equivalents and restricted cash	44	37	135	111	190
Short-term investments	230	95	63	74	—
Accounts and other receivables	1	544,000	1	173,000	—
Income tax and R&D incentive receivables	518,000	3	4	2	5
Prepaid expenses and other current assets	3	2	7	5	8
Total current assets	278	137	210	193	204
Property and equipment, net	312,000	413,000	651,000	1	1
Other assets	1	2	363,000	615,000	872,000
Total assets	280	139	211	207	219
Accounts payable	3	211,000	2	5	2
Accrued expenses and other current liabilities	12	10	10	12	10
Total current liabilities	15	10	12	17	18
Term loan, noncurrent	34	—	—	—	—
Other noncurrent liabilities	6	5	—	—	—
Total liabilities	55	16	17	22	20
Commitments and contingencies (Note 14)	—	—	—	—	—
Common stock, $0.0001 par value; 200,000,000 shares authorized; 110,882,735 and 72,352,701 shares issued and outstanding as of December 31, 2025 and 2024, respectively	11,000	7,000	7,000	5,000	4,000
Additional paid-in capital	879	690	665	568	497
Accumulated deficit	−649	−561	−466	−378	−293
Accumulated other comprehensive loss, net	−5	−5	−5	−5	−5
Total stockholders' equity	225	124	194	185	199
Total liabilities and stockholders' equity	280	139	211	207	219

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−88	−95	−88	−85	−97
Stock-based compensation expense	16	14	11	8	6
Depreciation of property and equipment	100,000	200,000	500,000	500,000	—
Accretion of discounts on short-term investments	−2	−4	−2	−698,000	—
Amortization of debt discount and costs	363,000	—	—	—	—
Loss on foreign currency exchange	160,000	−48,000	−154,000	34,000	384,000
Deferred income tax benefit	−681,000	—	—	—	—
Accounts receivable	−675,000	567,000	−938,000	256,000	4
Prepaid expenses and other assets	−204,000	5	−1	3	−6
Accounts payable	3	−2	−3	3	1
Accrued expenses and other liabilities	2	−112,000	−2	5	−2
Income tax and R&D incentive receivables	3	1	−1	3	2
Net cash used in operating activities	−68	−80	−76	−63	−78
Proceeds from sales and maturities of short-term investments	153	87	102	—	107
Purchases of short-term investments	−285	−116	−89	−73	−8
Purchases of property and equipment	−11,000	—	−47,000	−126,000	−12
Net cash used in investing activities	−132	−28	14	−73	88
Payments of deferred offering costs	−438,000	—	−195,000	—	−118,000
Proceeds from exercises of warrants	—	161,000	—	—	—
Proceeds from term loan	35	—	—	—	—
Payment for debt issuance costs	−1	—	—	—	—
Proceeds from issuance of common stock in at-the-market offerings, net	174	10	87	56	65
Proceeds from issuance of common stock from Employee Stock Purchase Plan	291,000	300,000	215,000	181,000	225,000
Proceeds from exercises of stock options	41,000	439,000	113,000	950,000	176,000
Payments for tax withholding in share-based compensation	−709,000	−850,000	−539,000	−516,000	—
Net cash provided by financing activities	207	10	86	57	65
Net increase (decrease) in cash and cash equivalents and restricted cash	7	−98	24	−79	74
Cash paid for interest	975,000	—	—	—	—
Cash received from income tax refunds	1	—	—	—	—
Deferred offering costs in accrued expenses and other current liabilities	111,000	—	—	—	—
Operating lease liability and right-of-use asset addition	—	1	—	—	72,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Altimmune, Inc.'s CIK number?

Altimmune, Inc.'s SEC CIK number is 0001326190 (1326190). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Altimmune, Inc.'s SEC filings?

All of Altimmune, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Altimmune, Inc. last report earnings?

Altimmune, Inc. (ALT) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001326190-26-000037). This is Altimmune, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Altimmune, Inc.'s most recent earnings 8-K?

Altimmune, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001326190-26-000037. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Altimmune, Inc.'s latest earnings 8-K →
Look up any company's CIK number →